Cocrystal Pharma Appoints Director Carol L. Brosgart

What Happened
Cocrystal Pharma, Inc. (COCP) announced in an 8-K filed August 18, 2026 that the Board appointed Carol L. Brosgart as a director, effective August 12, 2026. The filing was made under Item 5.02 (Election of Directors).

Key Details

• Appointment effective date: August 12, 2026.
• Director named: Carol L. Brosgart.
• The company disclosed there are no arrangements or understandings with others regarding her selection.
• The filing states there are no family relationships between Ms. Brosgart and any of the company’s directors or executive officers, and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.

Why It Matters
A board appointment is a governance change investors should note because directors help set strategy and oversight. The filing’s explicit statements about no selection arrangements, no family ties, and no reportable related-party transactions indicate the appointment does not introduce disclosed conflicts of interest. Investors tracking board composition, governance practices, or upcoming corporate decisions may consider this update when assessing company oversight.